Arcus Biosciences Inc., a global biopharmaceutical company, has announced new employment inducement grants. The company's Compensation Committee has granted stock options to two new employees, allowing them to purchase a total of 8,400 shares of the company's common stock at an exercise price of $9.85 per share, reflecting the closing price on June 9, 2025. Additionally, the employees were awarded restricted stock units for a total of 4,200 shares. These equity awards were issued under the company's 2020 Inducement Plan, approved by the Board of Directors in January 2020, in accordance with NYSE rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.